Guardant Health, Inc. (NASDAQ:GH) Stock Has Consensus Target Price of $188.12

Shares of Guardant Health, Inc. (NASDAQ:GH) have earned a consensus rating of “Moderate Buy” from the twenty-five analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, twenty-three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $188.12.

GH has been the subject of several research analyst reports. Royal Bank Of Canada increased their price objective on Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Stifel Nicolaus lifted their target price on shares of Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a report on Friday, July 31st. Barclays upped their price target on shares of Guardant Health from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. UBS Group increased their price target on shares of Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st.

Insider Buying and Selling at Guardant Health

In related news, Director Alex Azar, II sold 826 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total transaction of $144,550.00. Following the transaction, the director owned 825 shares of the company’s stock, valued at $144,375. This trade represents a 50.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Terilyn Monroe sold 46,300 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total value of $7,645,056.00. Following the transaction, the insider directly owned 22,979 shares in the company, valued at approximately $3,794,292.48. This represents a 66.83% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 178,755 shares of company stock valued at $30,040,636. Corporate insiders own 5.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. ABS Investment Management LLC acquired a new stake in shares of Guardant Health during the second quarter worth $345,069,000. MCF Advisors LLC grew its position in Guardant Health by 755.0% in the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after buying an additional 151 shares during the last quarter. TrinityBridge Ltd acquired a new position in Guardant Health in the 2nd quarter valued at $45,000. Global Retirement Partners LLC acquired a new position in Guardant Health in the 2nd quarter valued at $59,000. Finally, EFG International AG purchased a new position in Guardant Health during the 2nd quarter worth $60,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Performance

Guardant Health stock opened at $177.73 on Friday. The company has a market capitalization of $23.85 billion, a P/E ratio of -50.93 and a beta of 1.57. Guardant Health has a fifty-two week low of $60.45 and a fifty-two week high of $183.51. The stock has a 50-day simple moving average of $163.96 and a 200-day simple moving average of $131.91.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million for the quarter, compared to analysts’ expectations of $314.23 million. The company’s quarterly revenue was up 44.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.44) EPS. As a group, analysts forecast that Guardant Health will post -2.98 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc (NASDAQ: GH) is a precision oncology company that develops blood- and tissue-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients throughout the course of their disease. Its testing platforms analyze circulating tumor DNA and other genomic information to provide insights into a tumor’s molecular characteristics.

The company’s products include Guardant360 tests for comprehensive genomic profiling in advanced cancer, Guardant360 CDx, which is approved as a companion diagnostic for certain targeted therapies, and Guardant360 Response for assessing how a tumor may be responding to treatment.